OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ocular Therapeutix, Inc. To Contact The Firm

NEW YORK, July 7, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL).

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on May 5, 2017, the Company disclosed that U.S. Food and Drug Administration ("FDA") had found issues at its manufacturing plant.  Then on July 6, 2017, an article released on Seeking Alpha claimed, in part, that the Company "has been misleading investors about manufacturing," including that more than 50% of lots manufactured by the Company contain bad product.

On this news, Ocular's share price significantly declined, causing harm to investors.

If you invested in Ocular stock or options and would like to discuss your legal rights, click here:www.faruqilaw.com/OCUL.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ocular-therapeutix-investor-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-exceeding-50000-investing-in-ocular-therapeutix-inc-to-contact-the-firm-300484715.html

SOURCE Faruqi & Faruqi, LLP